mycophenolate mofetil [CellCept]
DrugConcentration-controlled
NCT Number: NCT00337493
This study will determine which, if any, allelic variants of mycophenolic acid (MPA) metabolizing enzymes, drug transporters and drug targets are associated with the observed variation in pharmacokinetic and pharmacodynamic outcomes observed with CellCept usage. Patients participating in study ML17225 will be eligible for this pharmacogenetic investigation, and will have one additional blood sample taken during the study. The anticipated time on study treatment in study ML17225 is 1-2 years, and the target sample size is 500+ individuals.
Looking for future studies?
Notify Me13 year–75 year
All sexes
Interventional
Phase 4
Birmingham, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Concentration-controlled
Reduced
Time frame: Throughout study
Time frame: Throughout study
Looking for future studies?
Notify MeHoffmann-La Roche
Industry
A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00531921
Behavior, Cardiovascular Diseases
Chicago, Illinois, United States
View Trial DetailsNCT00308802
Behavior, Chronic Disease
New Haven, Connecticut, United States
View Trial DetailsNCT01289717
Fibrosis, Kidney Transplant
Phoenix, Arizona, United States
View Trial DetailsNCT00337220
Chronic Disease, Disease Attributes
Chicago, Illinois, United States
View Trial Details